Species and response dependent differences in the effects of MAPK inhibitors on P2X 7 receptor function

British Journal of Pharmacology

Volumn 149, Issue 7, 2006, Pages 948-957

  Michel, A D ^a,b   Thompson, K M ^b,c   Simon, J ^b   Boyfield, I ^a   Fonfria, E ^a   Humphrey, P P A ^b,d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

^d THERAVANCE INC   (United States)

Author keywords

Ethidium bromide; MAP Kinase; P2X7 receptor; SB202190; SB203580

Indexed keywords

2' O (4 BENZOYLBENZOYL)ADENOSINE TRIPHOSPHATE; 3' O (4 BENZOYLBENZOYL)ADENOSINE TRIPHOSPHATE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE DERIVATIVE; CALCIUM ION; ETHIDIUM BROMIDE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PURINE P2X7 RECEPTOR; RECOMBINANT RECEPTOR; SB 242235; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BIOACCUMULATION; CALCIUM CELL LEVEL; CELL MEMBRANE PERMEABILITY; CHIMERA; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ELECTROPHYSIOLOGY; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; LEUKEMIA CELL; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CALCIUM SIGNALING; CELL LINE; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHIDIUM; HUMANS; IMIDAZOLES; INDICATORS AND REAGENTS; INTERLEUKIN-1BETA; MEMBRANE POTENTIALS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RECEPTORS, PURINERGIC P2; RECOMBINANT FUSION PROTEINS; SPECIES SPECIFICITY; TRANSFECTION;

EID: 33845193156     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706938     Document Type: Article

References (27)

1. Auger R, Motta I, Benihoud K, Ojcius DM, Kanellopoulos JM (2005). A role for mitogen-activated protein kinase (Erk1/2) activation and non-selective pore formation in P2X7 receptor-mediated thymocyte death. J Biol Chem 280: 28142-28151.
2. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ et al. (2000). Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthr Rheumat 43: 175-183.
3. Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S et al. (1998). Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92: 3521-3528.
4. Chessell IP, Simon J, Hibell AD, Michel AD, Barnard EA, Humphrey PP (1998). Cloning and functional characterisation of the mouse P2X7 receptor. FEBS Lett 439: 26-30.
5. Donnelly-Roberts DL, Namovic MT, Faltynek CR, Jarvis MF (2004). Mitogen-activated protein kinase and caspase signaling pathways are required for P2X7 receptor (P2X7R)-induced pore formation in human THP-1 cells. J Pharmacol Exp Ther 308: 1053-1061.
6. Faria RX, Defarias FP, Alves LA (2005). Are second messengers crucial for opening the pore associated with P2X7 receptor? Am J Physiol - Cell Physiol 288: C260-C271.
7. Frantz B, Klatt T, Pang M, Parsons J, Rolando A, Williams H et al. (1998). The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37: 13846-13853.
8. Gallagher TF, Fier-Thompson SM, Garigipati RS, Sorenson ME, Smietana JM, Lee D et al. (1995). 2, 4, 5-Triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg Med Chem Lett 5: 1171-1176.
9. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 195-198.
10. Hibell AD, Kidd EJ, Chessell IP, Humphrey PP, Michel AD (2000). Apparent species differences in the kinetic properties of P2X7 receptors. Br J Pharmacol 130: 167-173.
11. Hibell AD, Thompson KM, Xing M, Humphrey PP, Michel AD (2001). Complexities of measuring antagonist potency at P2X7 receptor orthologs. J Pharmacol Exp Ther 296: 947-957.
12. Jiang L-H, Rassendren F, Mackenzie A, Zhang Y-H, Surprenant A, North RA (2005). N-methyl-D-glucamine and propidium dyes utilize different permeation pathways at rat P2X7 receptors. Am J Physiol - Cell Physiol 289: C1295-C1302.
13. Khakh BS, Bao XR, Labarca C, Lester HA (1999). Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds. Nature Neurosci 2: 322-330.
14. Klapperstuck M, Buttner C, Bohm T, Schmalzing G, Markwardt F (2000). Characteristics of P2X7 receptors from human B lymphocytes expressed in Xenopus oocytes. Biochim Biophys Acta 1467: 444-456.
15. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C et al. (2002). Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62: 58-64.
16. Lundy PM, Nelson P, Mi L, Frew R, Minaker S, Vair C et al. (2004). Pharmacological differentiation of the P2X7 receptor and the maitotoxin-activated cationic channel. Eur J Pharmacol 487: 17-28.
17. Michel AD, Chessell IP, Humphrey PP (1999). Ionic effects on human recombinant P2X7 receptor function. Nauyn Schmied Arch Pharmacol 359: 102-109.
18. Michel AD, Kaur R, Chessell IP, Humphrey PP (2000). Antagonist effects on human P2X7 receptor-mediated cellular accumulation of YO-PRO-1. Br J Pharmacol 359: 513-520.
19. North RA (2002). Molecular physiology of P2X receptors. Phys Rev 82: 1013-1067.
20. Petrou S, Ugur M, Drummond RM, Singer JJ, Walsh Jr JV (1997). P2X7 purinoceptor expression in Xenopus oocytes is not sufficient to produce a pore-forming P2Z-like phenotype. FEBS Letts 411: 339-345.
21. Pfeiffer ZA, Aga M, Prabhu U, Watters JJ, Hall DJ, Bertics PJ (2004). The nucleotide receptor P2X7 mediates actin reorganization and membrane blebbing in RAW 264.7 macrophages via p38 MAP kinase and Rho. J Leuk Biol 75: 1173-1182.
22. Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A (1997). The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 272: 5482-5486.
23. Schilling WP, Wasylyna T, Dubyak GR, Humphreys BD, Sinkins WG (1999). Maitotoxin and P2Z/P2X(7) purinergic receptor stimulation activate a common cytolytic pore. Am J Physiol 277: C766-C776.
24. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (1996). The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272: 735-738.
25. Verhoef PA, Kertesy SB, Estacion M, Schilling WP, Dubyak GR (2004). Maitotoxin induces biphasic interleukin-1beta secretion and membrane blebbing in murine macrophages. Mol Pharmaocl 66: 909-920.
26. Virginio C, Church D, North RA, Surprenant A (1997). Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor. Neuropharmacol 36: 1285-1294.
27. Virginio C, MacKenzie A, Rassendren FA, North RA, Surprenant A (1999). Pore dilation of neuronal P2X receptor channels. Nature Neurosci 2: 315-321.